The study group was assigned to receive treatment with probiotics combined with Sertraline, while the control group was treated with Sertraline only. The initial dose of Sertraline (Pfizer) for adolescent MDD patients is usually 50 mg/d and reaches a fixed dose of 100 mg per day after 4 to 7 days. All MDD patients have a dose range of 100 to 200 mg per day according to the body weight, gender, treatment response, side effect, depression severity, which may be appropriately adjusted according to the patient’s tolerance, body weight, gender, treatment response, side effect and depression severity. Two and seven patients in the study and control groups, respectively, reached the highest therapeutic dose of 200 mg per day; the therapeutic doses of the rest patients were 100 or 150 mg per day. The side effects, reported in this study including hypersomnia, hypodynamia and constipation, are in control after Sertraline dosage adjustment and behavioral intervention (diet, exercise, etc.). Probiotics (combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus tablets, live, Hangzhou Yuanda Biology) were taken orally at 0.5 g at a time, twice daily. The treatment period of this study was 2 months.
Sertraline
Manufactured by Pfizer
Sourced in United States
Sertraline is a pharmaceutical laboratory equipment used in the production and analysis of the active pharmaceutical ingredient sertraline. It is a specialized device designed to facilitate the manufacturing, testing, and quality control processes associated with the development of the sertraline drug product.
Automatically generated - may contain errors
Lab products found in correlation
6 protocols using sertraline
1
Probiotic-Augmented Sertraline for Adolescent MDD
2
Chronic Stress Response Modulation by XPJY
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Adult male Sprague–Dawley rats (200–220 g) provided by Beijing Academy of Military Medical Sciences Laboratory Animal Centre were individually kept on a 12:12 h light/dark cycle in home cages with food and water available ad libitum except as described in stress. The experiment was approved by the Animal Ethic Committee of the university. Sixty rats (10 rats in each group) were randomly divided into six groups: control group receiving once-daily oral gavage (PO.) administration of distilled water for 21 days, CUS group receiving CUS and once-daily PO. administration of distilled water for 21 days, CUS + sertraline group receiving CUS and once-daily Po. sertraline at 10 mg/kg (Pfizer Inc., USA) for 21 days, CUS and XPJY groups receiving CUS and once-daily PO. XPJY at 0.35, 0.7 and 1.4 g/kg, respectively, for 21 days. The sertraline diluted in distilled water and XPJY were orally given 1 h before CUS exposure. The dosage “0.7 g/kg” has been calculated based mainly on the dosages of humans and animals. Then the double dosage was considered as one group, half dosage as another, hereby it works out that dose of XPJY is made as three groups: 0.35, 0.7 and 1.4 g/kg.
3
Placebo-Controlled Trials for Major Depression
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patient-level data from 28 industry-sponsored, placebo-controlled, acute phase trials for adults with major depression using the HDRS-17 as symptom inventory were obtained for citalopram (Lundbeck, Valby, Denmark), paroxetine (GlaxoSmithKline, Brentford, UK) and sertraline (Pfizer, New York, NY, USA). In two of the paroxetine studies and one sertraline study, fluoxetine was used as active control; while these patients were also included, those treated with non-SSRI comparators were not. To corroborate results obtained using data from the SSRI trials, we also analysed patient-level data from 13 trials comparing duloxetine to placebo (Lilly, Indianapolis, IN, USA). SSRI comparators (escitalopram, fluoxetine and paroxetine) were excluded. Both these data sets have been previously described in greater detail [7 , 8 (link)].
4
Sertraline Dosage-Dependent Therapy
5
Sertraline Effects on Forced Swim Test
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Sertraline (Pfizer Inc, CT, USA) was administered at a dose of 25 mg/kg i.p. 30 min prior to the forced-swim test. The FST was conducted as previously described [3 (link)]. Each session lasted for 300 s and was videorecorded. Unbiased analysis of total immobility time over the final 240 s was performed using the ForcedSwimScan (CleverSys Inc, VA, USA).
6
Pharmacological Modulation of Neurotransmitter Systems
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The following drugs were used: 6-hydroxydopamine (6-OHDA; H4381; Sigma-Aldrich, MO, USA) was dissolved in 0.9% NaCl, supplemented with 0.03% ascorbic acid. N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4; C8417; Sigma-Aldrich, MO, USA) and 5,7-dihydroxytryptamine (5,7-DHT; 37970; Sigma-Aldrich, MO, USA) were dissolved in 0.9% NaCl containing 0.1% of ascorbic acid. Formalin (F8775, Sigma-Aldrich, USA) was dissolved in 0.9% NaCl. Duloxetine (IN46285, Eli Lily and Company, Indianapolis, USA) was dissolved with 10% dimethylsulfoxide. Madopar (L-DOPA; Shanghai Roche Pharmaceutical Co. Ltd, Shanghai, China), pramipexole (Boehringer Ingelheim, Germany), droxidopa (Chongqing Shenghuaxi Pharmaceutical Co. Ltd, Chongqing, China), sertraline (Pfizer Inc., Liaoning, China), and clonidine (C7897; Sigma-Aldrich, MO, USA) were dissolved in saline.
The dosages used in the present study are as follows: Madopar (L-DOPA; i.p. 15 mg/kg); pramipexole (a D2/D3 receptor agonist; i.p. 1 mg/kg); droxidopa (a prodrug to NE; i.p. 10 and 20 mg/kg); clonidine (α2 receptor agonist; i.p. 200 μg/kg); duloxetine (a 5-HT and NE reuptake inhibitor; i.p. 10 mg/kg); sertraline (a selective serotonin reuptake inhibitor; i.p. 10 mg/kg). All the drugs were administered at a volume of 0.6–1 mL. The control group received the same volume of saline or 10% dimethylsulfoxide.
The dosages used in the present study are as follows: Madopar (L-DOPA; i.p. 15 mg/kg); pramipexole (a D2/D3 receptor agonist; i.p. 1 mg/kg); droxidopa (a prodrug to NE; i.p. 10 and 20 mg/kg); clonidine (α2 receptor agonist; i.p. 200 μg/kg); duloxetine (a 5-HT and NE reuptake inhibitor; i.p. 10 mg/kg); sertraline (a selective serotonin reuptake inhibitor; i.p. 10 mg/kg). All the drugs were administered at a volume of 0.6–1 mL. The control group received the same volume of saline or 10% dimethylsulfoxide.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!